Management team

Dag Aarsland

Professor Dag Aarsland joined the Institute of Psychiatry, Psychology and Neuroscience, King’s College London, in January 2016, after having served as Professor of Clinical dementia research at the Alzheimer’s Research Centre at Karolinska Institute in Stockholm, Sweden for five years. He also is the Research Director of the Centre for Age-Related Disease at Stavanger University Hospital. His dementia research career spans 25 years and includes a variety of translational clinical research, including leading several large multicentre biomarker and clinical trials. Improving clinical measurement and implementing novel digital devices has been an emerging interest during the last five years.

He has 400 PubMed listed papers, with a current H-factor of 105 and 47000 citations (Google scholar).

Vaibhav Narayan

Vaibhav is currently Vice President, Research Technology at Janssen R&D, and RADAR-CNS project co-lead.  The Neuroscience Therapeutic Area at Janssen is pioneering a more personalized and holistic approach to therapeutic intervention that goes ‘beyond the pill’, to offer data-driven and science-based ‘integrated solutions’ for preventing, diagnosing, treating, and monitoring CNS diseases. Vaibhav’s work is currently focused on utilizing state-of-the-art informatics methods and digital technologies for developing markers for early diagnosis, disease progression, drug response and treatment monitoring in Alzheimer’s and Mood; and to develop novel ‘point-of-need’ tools and technologies for management of adherence and prediction of relapse in patients with Schizophrenia. 

Vaibhav joined Johnson and Johnson from Eli Lilly and Co., where he headed the Discovery and Biomedical Informatics group to enable Lilly’s translational, biomarker, and tailored therapeutics strategies.  Prior to Lilly, Vaibhav held multiple leadership roles in various small to mid-size biotech companies such as Celera Genomics, CuraGen Corporation and Vertex Pharmaceuticals during which time he participated in multiple landmark ‘Big Biology’ projects, including sequencing, assembly and analysis of the human genome (Human Genome Project) and elucidation of the first complete protein-protein interaction map of a whole organism. 

Vaibhav obtained his PhD from Yale University jointly from the Departments of Chemistry, and Molecular Biophysics & Biochemistry in 1998, and an Executive MBA from Kellogg School of Management, Northwestern University in 2009. 

Rouba Kozak

Rouba obtained her Ph.D. in neuroscience and eating behaviour from Henri Poincare University in France, and has an extensive background in cognitive neuroscience with focus on translational research. Specifically, she has focused on bridging the gap between mechanistic studies in preclinical animal models, which provide exquisite detail on how brain circuits control discrete behaviours, and the measurement of functional impact of new therapies in clinical settings (e.g. neuro-degenerative and neuro-psychiatric patient populations).

Rouba’s scientific training ranged from studies on the mechanisms of obesity to cognition, employing state-of-the- art behavioral and neurochemical sampling techniques; providing her with a unique ability to conceptualize and design experiments in support of programs spanning the wide-ranging disease domains covered in the Takeda portfolio. She has utilized complex behavioural and neurochemical methods to test hypotheses regarding etiologies of neuropsychiatric disorders, as well as to develop translational models to test the efficacy of novel pharmacotherapeutics for the enhancement of cognitive function.

Pieter Jelle Visser

Dr. Visser is a clinical epidemiologist working on the early diagnosis and treatment of AD. He will co-lead WP5. He has ample experience in leading European prospective multicentre data collection studies in AD (Descripa, EDAR, EMIF) and in reusing existing data (EMIF-AD). He is academic co-PI of EMIF-AD and WP co-lead in EPAD and in ROADMAP (via Maastricht University affiliation).

Chris Hinds

Dr Hinds holds the Robertson Foundation Fellowship in Digital Phenotyping at the BDI. He is PI of the Digital Biomarkers for Dementia project co-funded (£1.2M) by Roche and Lilly, technical lead for the Oxford Cognitive Health and Neurosciences CTU, leads the devices theme for the OH BRC, leads True Colours, works with the OPDC, coordinates devices for the Deep & Frequent Phenotyping study, and the GameChanger project with the UK Alzheimer’s Society. He has a BA, MSc & PhD from the Oxford University Computing Laboratory.